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Abstract
Background: Delayed uterine involution has negative effects on the fertility of cows; use of prostaglandin
F2alpha alone as a single treatment has not been shown to consistently improve fertility. Combined
administration of PGF2alpha and PGE2 increased uterine pressure in healthy cows. We hypothesized, that
the combination of both prostaglandins would accelerate uterine involution and have, therefore, a positive
effect on fertility variables. In commercial dairy farming, the benefit of a single post partum combined
prostaglandin treatment should be demonstrated.
Methods: 383 cows from commercial dairy farms were included in this study. Uterine size and secretion
were evaluated at treatment 21–35 days post partum and 14 days later. Cows were randomly allocated
to one of three treatment groups: PGF2alpha and PGE2, PGF2alpha or placebo. For every animal
participating in the study, the following reproduction variables were recorded: Interval from calving to first
insemination, days open, number of artificial inseminations (AI) to conception; subsequent treatment of
uterus, subsequent treatment of ovaries. Plasma progesterone level at time of treatment was used as a
covariable. For continuous measurements, analysis of variance was performed. Fisher's exact test for
categorical non-ordered data and exact Kruskal-Wallis test for ordered data were used; pairwise group
comparisons with Bonferroni adjustment of significance level were performed.
Results: There was no significant difference among treatment groups in uterine size. Furthermore, there
was no significant difference among treatments concerning days open, number of AI, and subsequent
treatment of uterus and ovaries. Days from calving to first insemination tended to be shorter for cows
with low progesterone level given PGF2alpha and PGE2 in combination than for the placebo-group (P =
0.024).
Conclusion: The results of this study indicate that the administration of PGF2alpha or a combination of
PGF2alpha and PGE2 21 to 35 days post partum had no beneficial effect upon measured fertility variables.
The exception was a tendency for a shorter interval from calving to first insemination after administration
of the combination of PGF2alpha and PGE2, as compared to the placebo group. Further research should
be done in herds with reduced fertility and/or an increased incidence of postpartum vaginal discharge.
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Background
Delayed uterine involution causes economic losses to
dairy farmers. Uterine involution is normally completed
between 26 to 52 days post partum, but changes after 20–
25 days are often imperceptible [1]. Puerperal controls are
often done between 20–33 days post partum [2,3]. This
period overlaps with the period for normal postpartum
involution, but this window of time corresponds to the
period when post partum controls were described in Ger-
man [4] and Canadian studies [5]. First visit criteria
include evaluation of condition and involution of the
uterus and type of vaginal discharge [6,7]. Reevaluation
can be done 14 days later [2,8,9].
Inadequate production of endogenous prostaglandin has
been associated with delay in uterine involution post par-
tum [10,11]. Repeated administration of prostaglandin
F2α (PGF2α) twice daily from days 3 to 13 after calving
shortened the time needed for uterine involution by 6
days [12]. In the early post partum period, even single
administration of PGF2α does accelerate uterine involu-
tion and hasten a return to fertile ovarian cyclicity [10,12-
14]. Single administrations of PGF2α 14 to 28 days post
partum resulted in an enhanced first service conception
rate (68% as compared to 43% in control cows) [15]. The
advantages of this therapy, though, were restricted to
herds with below average conception rates (< 50% to first
insemination) [13]. Improved conception rate after single
administration of dinoprost in cows 14 to 28 days post
partum was particularly seen in cows with a serum proges-
terone value less than 0.5 ng/ml [15]. This fact demon-
strated that the benefit of a prostaglandin therapy was not
the consequence of luteolysis [15,16], but the beneficial
effect of PGF2α administered post partum is rather the
result of myometrial contraction and thereby accelerated
uterine involution [17,18].
In healthy experimental cows, prostaglandin E2 (PGE2)
increased uterine pressure in a dose-dependent manner if
administered intravenously [19]. Furthermore, there was
a cumulative effect related to uterine pressure, if PGF2α
and PGE2 were given in combination [20]. In humans,
the potency of prostaglandin E2 in stimulating smooth
muscle contractility exceeded that of PGF2α [21], whereas
the two substances were equally potent as to myometrial
contractility in cows near parturition [22]. In experimen-
tal cows, increased uterine pressure of PGE2 compared to
PGF2α was only measurable within the first 15 min after
administration [20]. Obviously, there are two different
receptors for PGE2 and PGF2α, but they also seem to be
able to bind to the same receptor with different affinities
[21,23]. PGE2 may even bind to the PGF2α – receptor with
higher affinity than PGF2α itself [21] and furthermore,
PGE2 is degraded via PGF2α [24]. In humans, it was, fur-
thermore, suggested that a greater number of PGE recep-
tors was responsible for the greater potency for PGE's in
stimulating uterine contractions compared to that of
PGF2α [25]. We decided to use a d-cloprostenol (as to
PGF2α : there are copies of the natural PGF2α and synthetic
more potent cloprostenols which are racemic or in the d-
form), as it can be used in a lower dose than the dl-clo-
prostenol, and it has an equal effect on myometrial con-
tractility [26].
It was the purpose of our study to evaluate the effect of a
single administration of PGF2α, or PGF2α and PGE2 in
combination (= PGF2α + E2), or placebo in dairy cows 21
to 35 days post partum. Our hypothesis was, that the com-
bination of both PG's had a beneficial effect on measured
fertility variables based on accelerated uterine involution
and cycle induction.
Materials and methods
Animals and including criteria
Data from 80 herds (10 – 50 cows per herd) participating
in the Fertility Service of the Clinic for Ruminants, Vetsu-
isse Faculty of the University of Berne were evaluated
(biweekly herd visits). Dairy cows undergoing routine
puerperal control 21 to 35 days post partum were
included, except for cows treated for puerperal endometri-
tis, cows with preceding caesarean section, retained foetal
membranes, dystocia, systemic antibiotic treatment and
systemic illnesses such as ketosis, displacement of the
abomasum, or acute mastitis. Furthermore, cows under
suspicion of not being healthy by the farmer were
excluded of the study because in these cases, the farmers
had called their veterinarian before our herd health visit to
treat these cows.
Study design
All trials were performed as double blind trials by
informed consent of the farmer (neither investigators nor
cows' owners were informed as to the group of treatment
used). Before drug administration, a blood sample was
taken for progesterone analysis later. Plasma progesterone
analysis was performed using an enzymeimmunoassay
with the second antibody technique. [27,28]. Every farm
was an entity starting systematically with treatment "A"
for the first cow, followed by "B", "C", "A", "B" and so on.
Treatment
Three groups of treatments were used: A = combination of
PGF2α (Genestran®, Dr. E. Gräub AG, Berne Switzerland,
150 μg d-cloprostenol IV) and PGE2 (2.5 mg dinopros-
tone IV), both substances administered in a volume of 2
ml each; B = placebo (NaCl 0.9% IV) in 2 portions of 2 ml;
C = PGF2α (Genestran®, 150 μg d-cloprostenol IV) and pla-
cebo (NaCl 0.9% IV), both substances in 2 portions of 2
ml.Reproductive Biology and Endocrinology 2006, 4:65 http://www.rbej.com/content/4/1/65
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Clinical variables
Cows were clinically examined by rectal and vaginal
exploration and vaginoscopy by one of four different
trained investigators working in herd health management.
All investigators received standard instructions before
starting work in the Fertility Service. Uterine size and loca-
tion, texture of uterine wall, symmetry of uterine horns,
cervical diameter, structures on ovaries and quantity and
quality of uterine secretion were recorded in a routine
manner. Within this study only uterine size and secretion
were analyzed for this study.
Uterine size
During rectal palpation, uterine size was scored as "under
1 examinators' hand", "pelvic", "abdominal-delimitable"
or "abdominal-not delimitable" [29].
Uterine secretion
Uterine secretion scored during vaginoscopy was catego-
rized as "normal", including clear mucus with some flakes
of pus or "purulent" meaning more than 50% of pus or
"lochiae" (reddish, brown, not malodorous) as reported
in previous studies [2,5,6,30].
Clinical reevaluation, side effects
All animals included in the study were clinically reevalu-
ated by vaginal and rectal palpation and vaginoscopy 14
days after the first clinical examination and treatment by
the same investigator. The same clinical variables were
evaluated and recorded similar to the first examination.
Owners were requested for recording any adverse side
effects following treatment and the injection site was
monitored during reevaluation.
Definitions
The changing of uterine size from first to second evalua-
tion was categorized as physiologic, healed or delayed
(Table 1).
The changing of uterine secretion was scored as physio-
logic, healed or pathologic (Table 2).
Fertility variables
Reproductive management in the herds included insemi-
nation on the first oestrus observed after a voluntary wait-
ing period of 42 days.
For every animal participating in the study, the following
variables were recorded: Interval from calving to first
insemination, days open, number of AI to conception,
subsequent treatment of uterus (local administration of
antibiotics or disinfectants); subsequent treatment of ova-
ries (PGF2α, progesterone-releasing intravaginal devices,
GnRH for the following reasons: cysts, not showing heat,
persistent corpus luteum (CL)).
Covariables
Plasma progesterone level on the day of drug administra-
tion was used as a covariable. Definition of "with CL" was
a palpable corpus luteum and a serum progesterone value
> 2 ng/ml.
Statistical analyses
Statistical analyses were performed with StatXact 6.0
(Cytel Inc., Cambridge MA, USA). For continuous meas-
urements, analysis of variance was performed. Fisher's
exact test for categorical non-ordered data and exact
Kruskal-Wallis test for ordered data were used; pairwise
group comparisons with Bonferroni adjustment of signif-
icance level were performed. Level of significance was p =
0.050 and with Bonferroni adjustment p < 0.017. All data
were calculated irrespective of progesterone value and
grouped in "with corpus luteum" or "without corpus
luteum".
Results
Animals
Data of 383 dairy cows from 80 farms were included in
this study. All Swiss dairy breeds were represented (Hol-
stein Friesian, Simmental, Red Holstein, Swiss Braunvieh
and their crosses), though, primarily Simmental × Red
Holstein crosses were present. Data of 163 animals were
excluded (total n = 546 cows) because of puerperal
endometritis, preceding caesarean section, retained foetal
membranes, birth problems and systemic illnesses. Data
were collected between May 2001 and April 2002 (12
months).
Drugs and study design
Cows were distributed to treatment groups A (n = 143), B
(n = 127) and C (n = 113).
Clinical reevaluation
From the 383 cows controlled in the first examination, 61
cows could not be reevaluated. Reasons were insemina-
tion in the meantime (9/14/10), selling (1/3/2) or cows
were on pasture (8/8/6) allocated in treatment groups A/
B/C respectively.
As to side effects reported by owners, there were 2 cows
dripping milk for 5 minutes after injection (treatment
group A, C) and 1 cow shivering for a couple of minutes
in treatment group A.
Clinical variables
Uterine size
Uterine size before drug administration and 14 days later
is specified in Table 3.Reproductive Biology and Endocrinology 2006, 4:65 http://www.rbej.com/content/4/1/65
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The progress from first to second evaluation was "physio-
logic" in A = 38%, B = 30% and C = 37% of the cows.
There were A = 22%, B = 25% and C = 30% of the cows
"healed". The progress was considered "delayed" in A =
40%, B = 45% and C = 33% of the cows. There were no
significant differences found among treatment groups,
neither all over (p = 0.377) nor divided in "with" or "with-
out corpus luteum".
Uterine secretion
Scoring of uterine secretion before drug administration
and 14 days later is specified in Table 4.
The progress from first to second evaluation was "physio-
logic" in A = 91%, B = 88% and C = 76% of the cows. In
the group of the healed cows there were A = 7%, B = 10%
and C = 20%. "Pathologic" were A = 2%, B = 2% and C =
4% of the cows. There was a significant difference all over
(P = 0.019), but only A versus C was significant (P =
0.005). If tests were performed in cows "with" or "without
corpus luteum", the result was only significant in "with-
out corpus luteum" (all over P = 0.002; A versus C, P =
0.001).
Fertility variables (Table 5)
Interval from calving to first insemination was (mean ±
standard deviation) 65 ± 24 in treatment group A, 68 ± 23
in group B and 64 ± 19 in group C. No significant differ-
ences were found among treatment groups all over (p =
0.306). In "without corpus luteum", days open were sig-
nificantly different (p = 0.034) and 10 days shorter for A
than for B (p = 0.024).
Days open were (mean ± standard deviation) 95 ± 46 in
treatment group A, 97 ± 49 in group B and 100 ± 53 in
group C. No significant differences were found among
treatment groups, neither all over (p = 0.947) nor divided
in "with" or "without corpus luteum".
Number of AI until conception (mean ± standard devia-
tion) was 1.8 ± 1 in treatment groups A and B and 1.9 ±
1.2 in group C. No significant differences were found
among treatment groups, neither all over (p = 0.582) nor
divided in "with" or "without corpus luteum".
Subsequent treatment of the uterus was performed in 6/3/
4 cows in treatment group A, B, C respectively. No signif-
icant differences were found among treatment groups,
neither all over (p = 0.613) nor divided in "with" or "with-
out corpus luteum".
Subsequent treatment of the ovaries was done in 59/42/
40 cows in treatment group A, B, and C, respectively. No
significant differences were found among treatment
groups, neither all over (p = 0.676) nor divided in "with"
or "without corpus luteum".
Covariables
Plasma progesterone level on the day of drug administra-
tion was (mean ± SD) 3.6 ± 1.3 ng/ml, 3.9 ± 1.8 ng/ml and
3.9 ± 1.6 ng/ml in treatment groups A, B and C "with cor-
pus luteum". Plasma progesterone level on the day of drug
administration was (mean ± SD) 0.8 ± 0.4 ng/ml, 0.9 ± 0.4
ng/ml and 0.8 ± 0.3 ng/ml in treatment groups A, B and C
without corpus luteum.
Table 1: Definition of progress from first examination of uterine size by rectal palpation 21 to 35 days post partum to second 
examination 14 days later.
First examination Second examination Definition of progress
under 1 examiners hand under 1 examiners hand physiologic
pelvic under 1 examiners hand healed
abdominal-delimitable under 1 examiners hand healed
abdominal-not delimitable under 1 examiners hand healed
all other combinations delayed
Table 2: Definition of progress from first examination 21 to 35 days post partum to second examination 14 days later of uterine 
secretion.
First examination Second examination Definition of progress
normal normal physiologic
purulent normal healed
lochiae normal healed
all other combinations pathologic
'Normal' means clear or clear with some flakes of pus. 'Purulent' means more than 50% of pus, 'lochiae' means reddish brown discharge, not 
malodorous.Reproductive Biology and Endocrinology 2006, 4:65 http://www.rbej.com/content/4/1/65
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Discussion
We could not corroborate our hypothesis: There was but
modest benefit from the use of PGF2α, or (PGF2α + E2) on
the fertility variables examined. There was a significant
difference among the 3 treatment groups in cows without
CL, but after Bonferroni adjustment, only a tendency for a
shorter interval from calving to first insemination for
(PGF2α + E2) as compared to placebo could be demon-
strated. No significant effect on the interval from calving
to first insemination was found for the cows in the PGF2α
– group as compared to placebo. This is in contrast to a
study by Gay and Upham, where a single injection of
PGF2α  at a median of 25 days post partum reduced
median time to first breeding by 4.5 days, but not median
time to conception or conception rate in clinically normal
cows with a palpable corpus luteum [31]. This fact might
be induced by the selection of cows: Gay and Upham only
chose cows with a palpable corpus luteum, where PGF2α
influenced oestrus induction [31]. In our study, the mod-
est benefit of (PGF2α + E2) in cows without a corpus
luteum could be explained by a favourable effect on myo-
metrial contractility, which is intensified for (PGF2α + E2)
as compared to PGF2α alone as shown in experimental
diestrus cows [20]. A positive effect of PGF2α on cows
Table 3: Number of cows at first examination 21 to 35 days post partum and 14 days later with uterine size (under 1 hand/pelvic/
abdominal-delimitable/abdominal-not delimitable) of treatment groups A, B and C. A is (PGF2α + E2), B is placebo and C is PGF2α 
alone.
Uterine size First examination Second examination
under 1 hand
A5 8 8 4
B4 7 6 4
C4 9 6 1
pelvic
A7 0 4 6
B6 2 4 6
C4 6 2 9
abdominal-delimitable
A1 1 0
B1 3 1
C9 3
abdominal-not delimitable
A40
B31
C7 3
Total 379 336
Data missing 44 7
Table 4: Number of cows at first examination 21 to 35 days post partum and 14 days later with uterine secretion (normal/purulent/
lochiae) of treatment groups A, B and C. A is (PGF2α + E2), B is placebo and C is PGF2α alone.
Uterine secretion First examination Second examination
normal
A 132 136
B 108 119
C8 7 1 0 4
purulent
A33
B71
C8 3
lochiae
A80
B1 1 1
C1 6 1
Total 380 368
Data missing 31 5Reproductive Biology and Endocrinology 2006, 4:65 http://www.rbej.com/content/4/1/65
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without corpus luteum as found in our study was already
described [32]. Increased uterine contraction and favour-
able factors involved in uterine defence mechanisms were
induced [8,32,33]. In another study, prostaglandin ther-
apy at day 26 and/or 40 independent of cycle state and
uterine health provoked a decreased calving to conception
interval as compared to saline treated control cows by 19
and 16 days, respectively [34].
Though the cows in our study were judged "healthy" by
their owners, there might have been cases of clinical and
subclinical endometritis. Rectal palpation and evaluation
of vaginal discharge are the basis for diagnosis of subclin-
ical endometritis and possible treatment of most cows in
the field [35]. In the cow, a moderate amount of purulent
discharge at oestrus or during uterine involution may be
part of the self-cleaning process [18]. It is, therefore, diffi-
cult to decide whether cows in good general condition but
suffering from purulent discharge are healthy (physio-
logic self-cleaning) or suffering from endometritis. The
incidence of post partum uterine infections in clinically
healthy cows has been assessed as reducing by self-cure
from 92% in the first week to 64% in week 4 and to 25%
in week 7 [13]. In a meta-analysis of the prostaglandin
effect administered post partum including 4052 cows
described in 10 papers, days open were shorter in treated
cows as compared to untreated cows (2.6 days) and this
difference tended to be greater for cows with an abnormal
puerperium (3.3 days) [36].
As the results of our study indicate that the administration
of PGF2α or (PGF2α + E2) in healthy dairy cows 21 to 35
days post partum had no beneficial effect upon fertility
variables, further research will be directed towards the
treatment of cows diagnosed with clinical endometritis
later than 50 days post partum with PGF2αand PGE2 and
its effect on reproductive variables.
Conclusion
The results of this study indicate that the administration
of PGF2α or a combination of PGF2α and PGE2 21 to 35
days post partum had no beneficial effect upon fertility
variables measured. This fact is supporting the theory, that
blanket treatments in healthy post partum cows should
not be performed. A tendency for a shorter interval from
calving to first insemination after administration of the
combination of PGF2α and PGE2, as compared to the pla-
cebo group does not justify this therapy. Contrarily, fur-
ther research should be done in herds with reduced
fertility and/or an increased incidence of postpartum vag-
inal discharge, as the combined prostaglandin treatment
may have a positive effect on cycle induction and empty-
ing the uterus of pathological contents.
Abbreviations
AI = artificial insemination; GnRH = Gonadotropin-
releasing hormone; IV = intravenously; PGE2 = prostag-
landin E2; PGF2α = prostaglandin F2α ; (PGF2α + E2) = the
combination of PGF2αand PGE2; CL = corpus luteum
Table 5: Number of days from calving to first insemination, number of days open and number of AI until conception for all cows in 
treatment groups A, B and C.
Calving to first insemination all cows Group of cows without CL p-value
A 65 ± 24 62 ± 18 all cows: p = 0.306
without CL:
p = 0.034
B 68 ± 23 71 ± 20
C 64 ± 19 67 ± 16 A-B: p = 0.024*
A-C: p = 0.406*
B-C: p = 0.953*
Days open
A 95 ± 46 93 ± 44 all cows: p = 0.947
without CL:
p = 0.802
B 97 ± 49 98 ± 45
C 100 ± 53 97 ± 44
Number of AI until conception
A 1.8 ± 1 1.7 ± 0.9 all cows: p = 0.582
without CL:
p = 0.915
B 1.8 ± 1 1.7 ± 1
C 1.9 ± 1.2 1.7 ± 1
A is (PGF2α + E2), B is placebo and C is PGF2α alone (mean ± SD) for all cows and group of cows without CL. Level of significance is p = 0.05 and 
with Bonferroni adjustment p < 0.017. * indicates the p-values for pairwise group comparisons of cows without CL.Reproductive Biology and Endocrinology 2006, 4:65 http://www.rbej.com/content/4/1/65
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